Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas: A challenging phase - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Mar 31, 2004

    Nicholas: A challenging phase

    Nicholas Piramal (NPIL) is one of the leading pharma companies in India with a strong presence in branded formulations markets, focusing on lifestyle drugs. It is one of the companies, which has chosen an inorganic growth path. Its acquisitions include pharmaceuticals business of ICI India, Global Bulk Drugs and Fine Chemicals, Sarabhai Pharmaceuticals. The company recently merged itself with Canere Actives and Fine chemicals.

    Business Segment % Sales
    Domestic 90.9
    Branded Formulations 72.4
    Generics 4.5
    API 1.2
    Vitamins & Fine Chemicals 6.1
    Diagnostics 6.7
    Exports 8.7
    Branded Formulations 2.4
    API 5.4
    Vitamins & Fine Chemicals 0.9

    On the exports front, the company is not as aggressive as other players. Unlike other companies, NPIL is entering into exports markets as a contract manufacturer to foreign companies. Given the natural advantage of Indian companies on costs front, contract-manufacturing offer promising growth potential. NPIL has recently signed a 5-year contract with AMO Corporation of USA for manufacturing of eye-care products to be sold in US, Europe and the Japanese markets. In this regard, the declared strategy of the company is to partner with the innovator company from the pre-launch stage to patent expiry. They will be involved with in the project throughout the value chain through contract research and contract manufacturing. According to the company, there are several other such deals in the pipeline.

    In the domestic market, the company has focused on branded formulations as the major business segment. Although NPIL is a strong player in the respiratory segment, its major thrust area for driving growth is life style segments like CVS (cardiovascular), CNS (Central Nervous System) and anti-diabetics (31% of revenues are derived from the lifestyle segment and the growth in this segment has been above the normal industry growth rates). Focus on lifestyle segment means above average growth rate for the company in future.

    The following table gives the revenue breakup from various segments and their growth rates in the first nine months of FY04.

    Therapeutic Area % Sales Growth
    Respiratory 22.9 19.1
    Anti-Infective 10.3 -2.5
    CVS 9.5 23.9
    CNS 9.4 13.4
    Nutritional 7.6 7.4
    Biotek 7.3 -4.8
    Anti-Diabetic 4.7 34.2
    Gastro-Intestinal 4.4 -2.5
    Dermatology 4.5 33.7
    NSAIDs 2.8 17.9
    Others 16.4 19.2

    Year 2005 is likely to bring new challenges and opportunities for domestic pharma majors. Although Nicholas Piramal has been one of the leading players in the domestic market, this new environment can bring about serious problems for the company considering the fact that there does not seem to be any clear cut R&D policy that company has adopted.

    At Rs 725, NPIL is trading at a P/E multiple of 19x FY04 our earnings estimates. Although the company has seen strong growth in revenues in recent times through acquisitions, lack of clear management direction post 2005 is the area of concern.



    Equitymaster requests your view! Post a comment on "Nicholas: A challenging phase". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)


    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Detailed Financial Information With Charts